Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The company has started rationing shots across the United Kingdom while advocates wonder why U.S. supplies haven’t been affected.
The deal focuses on Isis’s development of a new class of hepatitis B drugs, which could clear HBV antigens entirely from the blood.
By year’s end, a new crop of interferon-free hepatitis C combination therapies will likely hit the market.
Several changes are intended to improve its transparency.
A recent liver conference made it more clear than ever that the means to blow hepatitis C off the map is just within reach.
The FDA has upped its warning against two cancer drugs with that can reactivate hepatitis B in those who have previously been infected...
The GlaxoSmithKline (GSK) platelet drug eltrombopag (Promacta) has received approval from the Food and Drug Administration (FDA) to be...
Indonesian President Susilo Bambang Yudhoyono issued a decree in September that authorizes his government to use patents from several large ph...
GlaxoSmithKline is seeking approval from the Food and Drug Administration to use its thrombocytopenia drug eltrombopag as a treatment for...
Heplisav, a new hepatitis B virus (HBV) vaccine being development by Dynavax Technologies Corporation, is both well-tolerated and effective
In honor of World AIDS Day, AIDSmeds highlights the year’s top treatment stories.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.